BioWorld

Feb. 17, 2006

Tysabri Events For Biogen Idec Overshadow Year-End Figures

Despite a rocky year that began with the Tysabri market withdrawal, Biogen Idec Inc. reported strong fourth-quarter and full-year 2005 earnings driven by robust Avonex sales and lower expenses. (BioWorld Today) Read More

Onyx, Bayer Move Nexavar Into Yet Another Phase III

QLT’s BPH Drug Fails To Show Efficacy In Phase II

Pandemic, Defense VC Fund: $200M For Fighting Avian Flu

Holiday Notice

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...